文献速递神经技术与安全MR

内源性化学交换饱和转移MRI用于脑肿瘤诊断与治疗反应评估的系统综述

Endogenous Chemical Exchange Saturation Transfer MRI for the Diagnosis and Therapy Response Assessment of Brain Tumors: A Systematic Review.
PubMed 文献 · Radiol Imaging Cancer · 2020-01-31

该系统综述检索PubMed、Ovid Embase和Cochrane Library共430项研究,最终纳入36项,评估内源性化学交换饱和转移(CEST)MRI在脑肿瘤中的应用。纳入研究分为胶质瘤分级(19项,AUC 0.500-1.000)、预测胶质瘤分子亚型(5项,AUC 0.610-0.920)、区分不同脑肿瘤类型(7项,AUC 0.707-0.905)、治疗反应评估(3项,未给出AUC)及鉴别复发与治疗相关改变(5项,AUC 0.880-0.980)五组。相当比例研究存在高偏倚风险,诊断准确性尚不完全清楚,需进一步研究。

要点

  • 内源性CEST MRI在胶质瘤分级中AUC范围0.500-1.000,在鉴别复发与治疗相关改变中AUC范围0.880-0.980。
  • 预测胶质瘤分子亚型AUC 0.610-0.920,区分不同脑肿瘤类型AUC 0.707-0.905。
  • 相当比例纳入研究存在高偏倚风险,诊断准确性尚不完全清楚。

核心结论

  • 内源性CEST MRI可为脑肿瘤提供有价值且可能独特的信息,但其诊断准确性尚不完全清楚。
  • 需进一步研究评估该方法在支持分子遗传学诊断中的作用、探讨其在治疗后阶段的应用,并对技术进行比较以实现标准化。

研究设计与样本

  • 系统综述,检索PubMed、Ovid Embase和Cochrane Library数据库,共识别430项研究,最终纳入36项符合纳入标准的研究。
  • 两名研究者独立按照预设的排除和纳入标准筛选文献,并进行全面数据提取。
  • 所有纳入研究使用诊断准确性质量评估工具(Quality Assessment of Diagnostic Accuracy Studies)进行偏倚风险评估。

诊断标准与关键数值

  • 胶质瘤分级:19项研究,AUC范围0.500-1.000。
  • 预测胶质瘤分子亚型:5项研究,AUC范围0.610-0.920。
  • 区分不同脑肿瘤类型:7项研究,AUC范围0.707-0.905。
  • 治疗反应评估:3项研究,未给出AUC。
  • 鉴别复发与治疗相关改变:5项研究,AUC范围0.880-0.980。

临床应用与阅片要点

  • 内源性CEST MRI可能为脑肿瘤诊断与治疗反应评估提供有价值且可能独特的信息,但诊断准确性尚不完全清楚。
  • 作者指出需进一步研究评估该方法在支持分子遗传学诊断中的作用、探讨其在治疗后阶段的应用,并对技术进行比较以实现标准化。

局限性

  • 相当比例纳入研究存在高偏倚风险。
  • 内源性CEST MRI的诊断准确性尚不完全清楚。
  • 需进一步研究评估该方法在支持分子遗传学诊断中的作用、探讨其在治疗后阶段的应用,并对技术进行比较以实现标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To generate a narrative synthesis of published data on the use of endogenous chemical exchange saturation transfer (CEST) MRI in brain tumors.

MATERIALS AND METHODS: A systematic database search (PubMed, Ovid Embase, Cochrane Library) was used to collate eligible studies. Two researchers independently screened publications according to predefined exclusion and inclusion criteria, followed by comprehensive data extraction. All included studies were subjected to a bias risk assessment using the Quality Assessment of Diagnostic Accuracy Studies tool.

RESULTS: The electronic database search identified 430 studies, of which 36 fulfilled the inclusion criteria. The final selection of included studies was categorized into five groups as follows: grading gliomas, 19 studies (area under the receiver operating characteristic curve [AUC], 0.500-1.000); predicting molecular subtypes of gliomas, five studies (AUC, 0.610-0.920); distinction of different brain tumor types, seven studies (AUC, 0.707-0.905); therapy response assessment, three studies (AUC not given); and differentiating recurrence from treatment-related changes, five studies (AUC, 0.880-0.980). A high bias risk was observed in a substantial proportion of studies.

CONCLUSION: Endogenous CEST MRI offers valuable, potentially unique information in brain tumors, but its diagnostic accuracy remains incompletely known. Further research is required to assess the method's role in support of molecular genetic diagnosis, to investigate its use in the posttreatment phase, and to compare techniques with a view to standardization.Keywords: Brain/Brain Stem, MR-Imaging, Neuro-OncologySupplemental material is available for this article.© RSNA, 2020.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Okuchi S, Hammam A, Golay X, et al. Endogenous Chemical Exchange Saturation Transfer MRI for the Diagnosis and Therapy Response Assessment of Brain Tumors: A Systematic Review. Radiol Imaging Cancer. 2020. PMID: 33778693. doi:10.1148/rycan.2020190036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。